ArticleBMC pulmonary medicine2025
Pseudomonas aeruginosa-driven airway dysbiosis and machine learning prediction of acute exacerbations in non-cystic fibrosis bronchiectasis: a microbial-inflammatory signature approach.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiome and its role in bronchiectasis.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWhile Pseudomonas aeruginosa (PA) colonization is linked to poor outcomes in bronchiectasis, emerging evidence suggests that microbial community collapse-marked by diversity loss and depletion of commensal taxa-may better reflect disease progression than pathogen load alone. This study investigates whether airway microbiota dysbiosis driven by PA colonization induces ecological fragility and evaluates the predictive utility of integrating microbial diversity indices with systemic inflammation markers to forecast 1-year acute exacerbation risk using interpretable machine learning.
methodsBronchoalveolar lavage fluid (BALF) samples from 23 patients (8 PA-colonized, 15 non-colonized) underwent 16 S rRNA gene sequencing. Microbial diversity and taxonomic composition were analyzed. An eXtreme Gradient Boosting (XGBoost) model with SHapley Additive exPlanations (SHAP) analysis was constructed to assess exacerbation risk, focusing on microbial and inflammatory markers.
resultsPA-colonized patients (P1) exhibited significantly worse clinical severity than non-colonized patients (P2), with higher Bronchiectasis Severity Index scores (8.38 vs. 4.33, P < 0.01), poorer quality-of-life (SGRQ: 35.75 vs. 22.79; CAT: 24.00 vs. 16.26, P < 0.01), and elevated dyspnea (mMRC: 1.62 vs. 0.95, P < 0.05). P1 also had more acute exacerbations annually (retrospective: 3.00 vs. 1.20; prospective: 3.75 vs. 0.80, P < 0.05-0.001). Notably, P1 exhibited significantly reduced alpha diversity compared to P2 (Shannon index: 1.96 vs. 3.47; Simpson index: 0.46 vs. 0.77, P < 0.05). Weighted UniFrac PCoA revealed distinct clustering between groups (R²=0.162, P < 0.05). The XGBoost model, integrating microbial taxa relative abundances, alpha diversity indices, and inflammatory markers demonstrated robust performance in predicting 1-year acute exacerbation risk (AUC = 0.85). SHAP analysis identified the microbial diversity, rather than Pseudomona abundance was the most influential predictor of exacerbation risk.
conclusionsPA colonization disrupts airway microbial diversity and outcompetes commensal species in bronchiectasis, yet our XGBoost model reveals that ecological resilience-not pathogen load-best predicts exacerbation risk when integrated with inflammatory markers. This paradigm shift from pathogen-centric to ecosystem-driven risk assessment provides an actionable framework for personalized management and antibiotic stewardship in chronic airway diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.